Pavion Blue Capital LLC Raises Stake in Pfizer Inc. $PFE

Pavion Blue Capital LLC increased its position in shares of Pfizer Inc. (NYSE:PFE) by 8.8% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 9,787 shares of the biopharmaceutical company’s stock after purchasing an additional 788 shares during the period. Pavion Blue Capital LLC’s holdings in Pfizer were worth $237,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. GKV Capital Management Co. Inc. bought a new stake in shares of Pfizer during the 1st quarter valued at $27,000. Curio Wealth LLC raised its position in shares of Pfizer by 36,600.0% during the 2nd quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 1,098 shares during the period. Bayforest Capital Ltd bought a new stake in shares of Pfizer during the 1st quarter valued at $28,000. North Capital Inc. bought a new stake in shares of Pfizer during the 1st quarter valued at $28,000. Finally, Harbor Asset Planning Inc. bought a new stake in shares of Pfizer during the 2nd quarter valued at $29,000. 68.36% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several brokerages have recently commented on PFE. Bank of America raised their price objective on shares of Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a research report on Friday, October 3rd. Citigroup boosted their target price on shares of Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a report on Wednesday, August 6th. UBS Group reissued a “neutral” rating and issued a $28.00 target price on shares of Pfizer in a report on Wednesday, October 1st. Morgan Stanley lowered their target price on shares of Pfizer from $33.00 to $32.00 and set an “equal weight” rating on the stock in a report on Friday, October 10th. Finally, Wall Street Zen downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a report on Sunday, September 28th. Two analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Pfizer presently has an average rating of “Hold” and an average target price of $28.13.

Pfizer Price Performance

Pfizer stock opened at $24.76 on Tuesday. The company has a market cap of $140.75 billion, a price-to-earnings ratio of 13.17, a PEG ratio of 0.82 and a beta of 0.55. The firm’s fifty day moving average is $24.86 and its 200 day moving average is $24.21. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $29.17.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.58 by $0.20. The company had revenue of $14.65 billion for the quarter, compared to the consensus estimate of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. Pfizer’s revenue was up 10.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Sell-side analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Investors of record on Friday, November 7th will be paid a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, November 7th. This represents a $1.72 dividend on an annualized basis and a yield of 6.9%. Pfizer’s dividend payout ratio is presently 91.49%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.